These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20850301)

  • 1. Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.
    Bardelle C; Barlaam B; Brooks N; Coleman T; Cross D; Ducray R; Green I; Brempt CL; Olivier A; Read J
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6242-5. PubMed ID: 20850301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.
    Barlaam B; Ducray R; Lambert-van der Brempt C; Plé P; Bardelle C; Brooks N; Coleman T; Cross D; Kettle JG; Read J
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2207-11. PubMed ID: 21441027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
    J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines.
    Bardelle C; Coleman T; Cross D; Davenport S; Kettle JG; Ko EJ; Leach AG; Mortlock A; Read J; Roberts NJ; Robins P; Williams EJ
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5717-21. PubMed ID: 18851911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.
    Bardelle C; Cross D; Davenport S; Kettle JG; Ko EJ; Leach AG; Mortlock A; Read J; Roberts NJ; Robins P; Williams EJ
    Bioorg Med Chem Lett; 2008 May; 18(9):2776-80. PubMed ID: 18434142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
    Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
    J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
    Lafleur K; Dong J; Huang D; Caflisch A; Nevado C
    J Med Chem; 2013 Jan; 56(1):84-96. PubMed ID: 23253074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
    Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
    J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors.
    Kolb P; Kipouros CB; Huang D; Caflisch A
    Proteins; 2008 Oct; 73(1):11-8. PubMed ID: 18384152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
    Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
    J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
    Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
    Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
    Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
    Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
    J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.
    Miyazaki Y; Nakano M; Sato H; Truesdale AT; Stuart JD; Nartey EN; Hightower KE; Kane-Carson L
    Bioorg Med Chem Lett; 2007 Jan; 17(1):250-4. PubMed ID: 17027260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.